Non-small cell lung cancerProteomicsBackground: In a previous study (Goebel et. al, Cancer Genomics Proteomics 16:229-244, 2019), we identified 33 biomarkers for an early stage (I-II) Non-Small Cell Lung Cancer (NSCLC) test with 90% accuracy, 80.3% sensitivity, and 95.4% specificity. ...
Small-cell lung cancer accounts for only approximately 15% of all cases of lung cancer. People should seek medical care when experiencing shortness of breath, unexplained weight loss, chest pain that doesn't go away or coughing up large amounts of blood. Chemotherapy is the most effective ...
The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients poses significant challenges. To date, analyses of tumor biopsies are the only parameter u...
Invasion of blood vessels as significant prognostic factor in radically resected T1-3N0M0 non-small-cell lung cancer. ≤0.01), whereas lymph vessel invasion had no significant impact on survival. Multivariate analysis covering T stages, histological subtypes, location of t... S Gabor,H Renner,H...
Blood tests are done to get information about your overall health. A sputum sample may be tested for cancer cells. A biopsy , or sample of lung tissue, can be taken to test for cancer. A biopsy can be done through several procedures such as bronchoscopy, endobronchial ultrasound, or medias...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose...
Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune cells and PD-L1 on cancer cells have been used to successfully treat non-small cell lung cancer (NSCLC), including some durable responses lasting years. Two drugs, nivolumab and pembrolizumab, are ...
Blood IDH1 Level as a Diagnostic Biomarker for Non-Small Cell Lung CancerBlood IDH1 Level as a Diagnostic Biomarker for Non-Small Cell Lung Cancer发表人: 健康管理专家 阅读量: 110人The diagnosis of non-small cell lung cancer (NSCLC) relies heavily on the availability of effective biomarkers. Re...
Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST (NCT02848651), an open-label, phase 2 trial that evaluated bTMB as a predictive biomarker for first-line atezolizumab monotherapy in locally advanced or metastatic stage IIIB–IVB non-small cell lung cancer (n = 152)...
Keywords: lung cancer; biomarkers; cytology; liquid biopsy; diagnosis 1. Introduction In recent years, therapeutic strategies for advanced-stage non-squamous non-small-cell lung carcinoma (NS-NSCLC), in particular lung adenocarcinoma, have evolved in a dramatic way due to the development of target...